ITRM910363A1 - Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi - Google Patents

Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi

Info

Publication number
ITRM910363A1
ITRM910363A1 IT000363A ITRM910363A ITRM910363A1 IT RM910363 A1 ITRM910363 A1 IT RM910363A1 IT 000363 A IT000363 A IT 000363A IT RM910363 A ITRM910363 A IT RM910363A IT RM910363 A1 ITRM910363 A1 IT RM910363A1
Authority
IT
Italy
Prior art keywords
degenaration
myopathies
neuronal
treatment
therapeutic agents
Prior art date
Application number
IT000363A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to ITRM910363A priority Critical patent/IT1245699B/it
Publication of ITRM910363A0 publication Critical patent/ITRM910363A0/it
Priority to EP92830259A priority patent/EP0516594A1/en
Priority to ZA923829A priority patent/ZA923829B/xx
Priority to CA002069520A priority patent/CA2069520A1/en
Priority to JP4136886A priority patent/JPH05148200A/ja
Priority to US07/890,009 priority patent/US5227518A/en
Priority to IE169992A priority patent/IE921699A1/en
Publication of ITRM910363A1 publication Critical patent/ITRM910363A1/it
Application granted granted Critical
Publication of IT1245699B publication Critical patent/IT1245699B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ITRM910363A 1991-05-29 1991-05-29 Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi IT1245699B (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITRM910363A IT1245699B (it) 1991-05-29 1991-05-29 Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
EP92830259A EP0516594A1 (en) 1991-05-29 1992-05-26 L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
ZA923829A ZA923829B (en) 1991-05-29 1992-05-26 L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
CA002069520A CA2069520A1 (en) 1991-05-29 1992-05-26 L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
JP4136886A JPH05148200A (ja) 1991-05-29 1992-05-28 筋障害および神経退行変性の処置のためのアシル−ｌ−カルニチン誘導体
US07/890,009 US5227518A (en) 1991-05-29 1992-05-29 L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis
IE169992A IE921699A1 (en) 1991-05-29 1992-07-01 L-carnitine derivatives as therapeutical agents for treating¹myopathies and neuronal degeneration and for inhibiting¹proteolysis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM910363A IT1245699B (it) 1991-05-29 1991-05-29 Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi

Publications (3)

Publication Number Publication Date
ITRM910363A0 ITRM910363A0 (it) 1991-05-29
ITRM910363A1 true ITRM910363A1 (it) 1992-11-29
IT1245699B IT1245699B (it) 1994-10-14

Family

ID=11400163

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM910363A IT1245699B (it) 1991-05-29 1991-05-29 Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi

Country Status (7)

Country Link
US (1) US5227518A (it)
EP (1) EP0516594A1 (it)
JP (1) JPH05148200A (it)
CA (1) CA2069520A1 (it)
IE (1) IE921699A1 (it)
IT (1) IT1245699B (it)
ZA (1) ZA923829B (it)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1261230B (it) * 1993-04-08 1996-05-09 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione di l-(-)-carnitina a partire da suoi precursori aventi opposta configurazione.
EP0681839A3 (en) * 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
US5681739A (en) * 1995-05-25 1997-10-28 Lockheed Idaho Technologies Company Method for in situ or ex situ bioremediation of hexavalent chromium contaminated soils and/or groundwater
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
DK0951909T4 (da) * 1998-03-19 2011-01-24 Sigma Tau Ind Farmaceuti Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
DE60009274T2 (de) * 1999-04-14 2005-01-27 Shell Internationale Research Maatschappij B.V. Verfahren zur grundwassersanierung
IT1317042B1 (it) * 2000-06-14 2003-05-26 Biosalts Srl Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
IT1317062B1 (it) 2000-07-14 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare utile per prevenire le disfunzioni epatiche ebiliari comprendente una alcanoil l-carnitina.
US8173618B2 (en) 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8597640B2 (en) 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
EP3855944A4 (en) * 2018-10-29 2022-06-29 Lonza Consumer Health Inc. Method and composition for increasing the bioavailability of carnitine
CN109395084A (zh) * 2018-11-14 2019-03-01 威海市千谷生物科技有限公司 一种溶脂线和溶脂液及利用其的埋线减肥方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727151A (en) * 1974-06-24 1988-02-23 Interx Research Corporation Labile quaternary ammonium salts as prodrugs
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
EP0150688B1 (en) * 1983-12-28 1987-04-22 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
DE3400514A1 (de) * 1984-01-10 1985-07-18 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeure-derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
DE3623215A1 (de) * 1986-07-10 1988-01-21 Henkel Kgaa Neue quartaere ammoniumverbindungen und deren verwendung
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1224842B (it) * 1988-12-27 1990-10-24 Sigma Tau Ind Farmaceuti Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso

Also Published As

Publication number Publication date
EP0516594A1 (en) 1992-12-02
CA2069520A1 (en) 1992-11-30
US5227518A (en) 1993-07-13
IE921699A1 (en) 1992-12-02
ITRM910363A0 (it) 1991-05-29
ZA923829B (en) 1993-01-27
JPH05148200A (ja) 1993-06-15
IT1245699B (it) 1994-10-14

Similar Documents

Publication Publication Date Title
ITRM910363A1 (it) Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
ITMI920528A0 (it) 14-beta idrossi-10-de acetil-baccatina iii, suoi derivati, loro preparazione ed impiego terapeutico
ITMI911299A0 (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
ITRM920270A0 (it) Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale.
PL310348A1 (en) Substituted derivatives of azolone for use in treating diseases caused by heliobacter
IT1221826B (it) Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
ITBG910042A0 (it) Preparati farmaceutici per uso topico destinati al trattamento della psoriasi e della dermatite atopica
IT8848717A0 (it) Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
ITMI911096A0 (it) Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
ITMI910456A0 (it) Composizione farmaceutica per il trattamento della cataratta
ITMI911470A0 (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
IT1229491B (it) Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
ITMI931019A1 (it) Derivati del cicloeptimmidazolo, metodo per la loro produzione e agenti terapeutici contenenti questi composti
IT1230141B (it) Impiego di derivati della fosfatidil carnitina per la preparazione di composizioni farmaceutiche aventi attivita' nella terapia delle patologie dell'uomo associate con un danno neuronale.
IT1150396B (it) Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
ITRM950544A0 (it) Uso della l-carnitina di suoi derivati e di loro sali farmaceuticamen-te accettabili in combinazione con farmaci antiretrovirali per ridurrei livelli di ceramide e potenziare l'attivita' di tali farmaci antire-trovirali per il trattamento terapeutico dell'invenzione...
ITMI931723A0 (it) Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
IT8948702A0 (it) Derivati gangliosidici, loro uso quali agenti terapeutici, procedimento per la loro produzione e composti farmaceutici che li contengono
ITMI991713A0 (it) Derivati 2-amminotetralinici per la terapia del glaucoma
ITMI911122A0 (it) Composizioni per la terapia topica delle ustioni
ITMI941541A0 (it) Derivati del carbossimetilidenecicloptimmidazolo procedimento di fabbricazione dei derivati e agenti terapeutici che contengono questi composti
IT1229121B (it) Impiego, in campo umano, di un derivato a struttura indolica, del tipo della triptamina, in particolare di melatonina (mlt), o n-acetil-5-metossitriptamina, a scopi terapeutici e quale farmaco per la cura delle sindromi iperlipidemiche, iperuricemiche, ipercreatininemiche ed ipertiroidee
IT9022309A0 (it) Composizione terapeutica per il trattamento della vitiligine
IT8820483A0 (it) Impiego della carnitina e derivati per la preparazione di composizioni atte al trattamento della cellulite.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970416